| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790520 | American Journal of Ophthalmology | 2018 | 21 Pages |
Abstract
Difluprednate was associated with an improvement in uveitic CME and could be a reasonable first-line therapy. IOP should be closely monitored.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Julie M. Schallhorn, Katherine M. Niemeyer, Erica N. Browne, Parth Chhetri, Nisha R. Acharya,